A comparative study of two levonorgestrel-containing hormone replacement therapy regimens on efficacy and tolerability variables

Maturitas

Volumn 28, Issue 2, 1997, Pages 169-179

  Graser T ^a   Rossner P ^b   Schubert, K ^c   Muller A ^a   Bonisch U ^d   Oettel, M ^a  

^a BAYER PHARMA AG   (Germany)

^b Prenzlauer Promenade 143   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d TriLife   (Germany)

Author keywords

Estradiol valerate; Hormone replacement therapy; Kupperman Index; Levonorgestrel; Sequential regimen; Serum lipids

Indexed keywords

ESTRADIOL VALERATE; ESTRADIOL VALERATE PLUS NORGESTREL; LEVONORGESTREL; UNCLASSIFIED DRUG;

ARTICLE; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SUBSTITUTION THERAPY;

COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LEVONORGESTREL; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; MIDDLE AGED; PATIENT DROPOUTS; POSTMENOPAUSE; PROGESTERONE CONGENERS; TIME FACTORS; UTERINE HEMORRHAGE;

EID: 0345215171     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(97)00069-8     Document Type: Article

References (43)

1. Hartwell D., Hassager C., Overgard K., Riis B.J., Podenphant J.R., Christiansen C. Vitamin D metabolism in osteoporotic women during treatment with estrogen, an anabolic steroid, or calcitonin. Acta Endocrinol Copenh. 122:1990;715-721.
2. Kuhl H. Myocardinfarkt in der Postmenopause. Östrogene senken das Risiko drastisch. Ther. Woche. 41:1991;2007-2012.
3. Feldmann HU. BGA zur peri- und postmenopausalen Hormonsubstitution: Alle Östrogene müssen mit einem Gestagen kombiniert werden. Gyne Sonderausgabe 1994:1-2.
4. Christensen N.C., Davidsen P.C., Secher N.J., Pedersen G.T. Serum lipids during oestradiol valerate/levonorgestrel treatment of menopausel women. Acta Obstet Gynec Scand. 54:1975;213-216.
5. Hirvonen E., Mälkonen M., Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med. 304:1981;560-563.
6. Christiansen C., Riis B.J. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins and bleeding pattern. Br J Obstet Gynaecol. 97:1990;1087-1092.
7. Edgren R.A., Smith H., Peterson D.L., Carter D.L. The biological effects of a series of 13β-substituted gonanes related to norethisterone (17α-ethynyl-19-nor-testosterone). Steroids. 2:1993;319-335.
8. 4-3-oxo steroids. Proc Soc Exp Biol (NY). 123:1966;788-790.
9. Marslew U., Munk-Nielsen N., Nilas L., Riis B.J., Christiansen C. Bleeding pattern and climacteric symptoms during different sequential combined HRT regimens in current use. Maturitas. 19:1994;225-237.
10. Kuhl H. Atherosklerose-Prophylaxe durch Östrogensubstitution. Geburtsh Frauenheilk. 48:1988;745-756.
11. Miller V.T., Muesing R.A., LaRosa J.C., Stoy D.B., Phillips E.A., Stillmann R.J. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions and apolipoprotein A1. Obstet Gynecol. 77:1991;235-240.
12. Hauser G.A., Huber I.C., Keller P.J., Lauritzen C., Schneider H.P.G. Evaluation der klimakterischen Beschwerden. Zentralblatt für Gynäkol. 116:1994;16-23.
13. Büttner J, Rommel K, Stamm D, Wisser H. Charakterisierung der fachgerechten klinisch-chemischen Untersuchung. In: Deutsche Gesellschaft für Klinische Chemie e.V. Cologne: Klinische Chemie, eine Dokumentation, 1979.
14. Stamm D. Neues Konzept für die Qualitätssicherung klinisch-chemischer Befunde aufgrund ärztlicher Erfordernisse basierend auf Referenzmethoden-Werten. Mitt Dtsch Ges Klin Chem. 14:1983;5-16.
15. Trinder P. Determination of glucose in blood using glucose oxidase with an oxygen acceptor. Ann Clin Biochem. 6:1969;24-27.
16. Roeschlau P., Bernt E., Gruber W. Enzymatic determination of total cholesterol in serum. J Clin Chem Clin Biochem. 12:1974;226.
17. Buccolo G., David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 19:1973;476-482.
18. Assman G., Schriewer H. Performance and limitations of the analysis of HDL-cholesterol. J Clin Chem Clin Biochem. 19:1981;1-6.
19. 3 quantitation method based on precipitation with polyethylene glycol. Clin Chim Acta. 148:1985;139-147.
20. Seidel J., Haegele E.O., Ziegenhorn J., Wahlefeld A.W. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 29:1983;1075-1080.
21. Wieland H., Seidel D. A simple specific method for precipitation of low density lipoproteins. J Lipid Res. 24:1983;904-909.
22. Sternberg J.C. A rate nephelometer for measuring specific proteins by immunoprecipitin reactions. Clin Chem. 23:1977;1456-1464.
23. Gambrell R.D. Jr. Prevention of endometrial cancer with progestogens. Maturitas. 8:1986;159-168.
24. Raudaskoski T.H., Tomás E.I., Paakkari I.A., Kauppila A.J., Laatikainen T.J. Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device. Maturitas. 22:1995;47-53.
25. Breckwoldt M., Keck C., Karck U. Benefits and risks of hormone replacement therapy (HRT). J Steroid Biochem Mol Biol. 53:1995;205-208.
26. Göretzlehner G., Nikschick S., Krause B. Hormonsubstitution im Klimakterium mit Klimonorm. Medicamentum. 9:1992;244-251.
27. Dören M., Reuther G., Minne H.W., Schneider H.P. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol. 173:1995;1446-1451.
28. Barr D.R., Russ E.M., Eder H.A. Influence of oestrogen on lipoproteins in atherosclerosis. Trans Assoc Am Physicians. 65:1952;102-111.
29. Knopp R.H., Xiaodong Z., Lau J., Walden C. Sex hormones and lipid interactions: implications for cardiovascular disease in women. The Endocrinologist. 4:1994;286-301.
30. Punnonen R.H., Jokela H.A., Dastidar P.S., Nevala M., Laippala P.J. Combined oestrogen-progestin replacement therapy prevents atherosclerosis in postmenopausal women. Maturitas. 21:1995;179-187.
31. Tonstad S., Ose L., Gorbitz C., Djoseland O., Bard J.M., Fruchart J.C. Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolaemia among postmenopausal women. J Intern Med. 238:1995;39-47.
32. Lobo R.A. The role of progestins in hormone replacement therapy. Am J Obstet Gynaecol. 166:1992;1997-2004.
33. Tikkanen M.J. Estrogens, progestins and lipid metabolism. Maturitas. 23(Suppl):1996;S51-S55.
34. Hassing Nielsen F., Honoré E., Kristoffersen K., Secher N.J., Thomsen Pedersen G. Changes in serum lipids during treatment with levonorgestrel, oestradiol valerate and cycloprogynon. Acta Obstet Gynecol Scand. 56:1977;367-370.
35. The Lipid Research Clinics Program Epidemiology Committee Plasma lipid distribution in selected North American populations: the Lipid Research Clinics Program prevalence study. Circulation. 60:1979;427-439.
36. Husmann F. Pathogenese, Früh- und Spätkomplikationen, Therapie. In: Pamminger K, editor. Climactericum Feminale. Konzept and Bücher Leonberg, 1995:81-89.
37. Sandkamp M., Funke H., Schulte H., Kohgler E., Assmann G. Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem. 36:1990;20-23.
38. Caruso M.G., Berloco P., Notarnicola M., Di Leo A. Lipoprotein (a) serum levels in post-menopausel women treated with oral estrogens administered at different times. Horm Metab Res. 26:1994;379-382.
39. Hermann W, Quast S, Kießling S, Wolter K, Hahnemann H. Is unbound apo(a) of diagnostic interest? Abstracts of 9th International Symposium on Lipoproteins and Atherosclerosis, Dresden, 1997;P17:55.
40. Kuhl H. Die Bedeutung der Antioxidantien. Zentralbl Gynäkol. 119:1997;1-5.
41. Soma M., Fumagalli R., Paoletti R., Meschia R., Maini M.C., Crosignani P., Ghanem K., Gaubatz J., Morrisett D.D. Plasma lipoprotein (a) concentration after oestrogen and progestagen in postmenopausal women. Lancet. 337:1991;612.
42. Mendoza S., Velazquez E., Osona A., Hamper T., Glueck C.J. Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein (a). J Lab Clin Med. 123:1994;837-841.
43. Collins P. Vascular aspects of estrogen. Maturitas. 23:1996;217-226.